HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry
Authors:
Open Access
- 14 December 2022
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (2) , 1-9
Abstract
The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter‑observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. Implementing automatic algorithms to classify IHC biomarkers is crucial for typifying the tumor and deciding on therapy for each patient with better performance. The present study aims to demonstrate that, using an explainable Machine Learning (ML) model for the classification of HER2 photomicrographs, it is possible to determine criteria to improve the value of IHC analysis. We trained a logistic regression‑based supervised ML model with 393 IHC microscopy images from 131 patients, to discriminate between upregulated and normal expression of the HER2 protein. Pathologists' diagnoses (IHC only) vs. the final diagnosis complemented with FISH (IHC + FISH) were used as training outputs. Basic performance metrics and receiver operating characteristic curve analysis were used together with an explainability algorithm based on Shapley Additive exPlanations (SHAP) values to understand training differences. The model could discriminate amplified IHC from normal expression with better performance when the training output was the IHC + FISH final diagnosis (IHC vs. IHC + FISH: area under the curve, 0.94 vs. 0.81). This may be explained by the increased analytical impact of the membrane distribution criteria over the global intensity of the signal, according to SHAP value interpretation. The classification model improved its performance when the training input was the final diagnosis, downplaying the weighting of the intensity of the IHC signal, suggesting that to improve pathological diagnosis before FISH consultation, it is necessary to emphasize subcellular patterns of staining.Keywords
This publication has 62 references indexed in Scilit:
- Perceived and Objective Breast Cancer Risk Assessment in Chilean Women Living in an Underserved AreaCancer Epidemiology, Biomarkers & Prevention, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Association between breast cancer subtypes and response to neoadjuvant anastrozoleSteroids, 2011
- HER2 Evaluation and Its Impact on Breast Cancer Treatment DecisionsPublic Health Genomics, 2011
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2010
- Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor SpecimensPathology Research International, 2010
- Quantitative Colocalization Analysis of Confocal Fluorescence Microscopy ImagesCurrent Protocols in Cell Biology, 2008
- Current issues in ER and HER2 testing by IHC in breast cancerLaboratory Investigation, 2008
- Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast CancerClinical Chemistry, 2007
- Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and PrognosisJNCI: Journal of the National Cancer Institute, 2005